EUVIMED · CrossrefZeitschrift
Journal for ImmunoTherapy of Cancer
ISSN 2051-1426 · BMJ
Neueste Artikel
Multi-omics characterization of the tumor microenvironment in thyroid cancer with multi-organ metastasis
Enhanced melanoma-specific cytotoxic T-cell expansion and the clinical outcomes with simlukafusp alfa and pembrolizumab following checkpoint inhibitor progression
Harnessing inflammatory monocytes to overcome resistance to anti-PD-1 immunotherapy
Immune-related hepatitis and HLA-DQB1*06:01 as potential predictor biomarkers in East Asian patients with lung cancer treated with ICIs: a large-scale real-world study
Immune cell atlas reveals mechanisms of immune evasion and LAG-3 as a novel target in mouse models of breast cancer metastasis
Midkine identifies a Treg-enriched immune-evasive phenotype associated with poor outcomes in clear cell renal cell carcinoma
Integrating PET/CT and correlative biomarkers for prospective evaluation of extramedullary disease in relapsed/refractory B-ALL: implications for CAR T-cell therapy
Integrated tumor and circulating immune profiling in the NEO-CESQ trial of perioperative cemiplimab for resectable cutaneous squamous cell carcinoma
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of multiple myeloma, version 2.0
Antiviral humoral immunity as biomarker and effector in oncolytic adenovirus TILT-123 therapy
Multi-omics reveals PCSK9 induces precursor-like macrophage M2 polarization to exacerbate immunosuppression in peritoneal metastasis
Lost in translation: why cytokine release syndrome reporting fails clinical trials
Spatial transcriptomics reveals divergent interferon and tissue remodeling programs in immune checkpoint inhibitor-induced subacute cutaneous lupus erythematosus
CD39, CD73, and CD38 track tumor burden and reveal immune remodeling during mogamulizumab therapy in Sézary syndrome
Steering the immune response: cancer vaccines and the next era of cancer immunotherapy
Epigenetic targeting of an HBO1-H3K9la-CHI3L1 axis reduces regulatory B cell-mediated CD8 + T cell dysfunction in lung adenocarcinoma
Promoting tumor antigen presentation unleashes therapeutic efficacy of Tgfbr2 -deficient TCR-engineered T cells in pancreatic ductal adenocarcinoma
Epigenetic demethylation sensitizes cancer cells to CAR-M triggered pyroptosis and remodels inflammatory immune responses in the tumor microenvironment to potentiate CAR-M cell therapy
SIRPA drives T cell apoptosis to promote immune evasion in hepatocellular carcinoma
Enhanced tumor metastasis driven by the crosstalk between melanoma cells and tumor-associated macrophages: insights into the CXCL10/CXCR3-hnRNP C-MIF axis
Ectopic rabphilin-3A expression in lung adenocarcinoma associated with paraneoplastic arginine vasopressin deficiency during anti-PD-L1 therapy: a case report
Epigenetic repression of oncogenic signaling defines immune-permissive tumor states associated with response to immune checkpoint inhibitors in advanced NSCLC
Gαi3 acts as a metabolic checkpoint orchestrating TAMs immunosuppression and lipid metabolism in glucose-deprived hepatocellular carcinoma
Immunostimulatory gene therapy with chemotherapy remodels pancreatic tumors and induces immune signatures associated with prolonged survival
HIF1A + CSF3R + neutrophils-dominated hypoxic niche induced metabolic reprogramming for neoadjuvant therapy resistance in NSCLC
Comparative clinical outcomes and single-cell profiling of CD19 CAR-T versus blinatumomab for relapsed/refractory B-ALL
Screening of known gut microbiome-derived metabolites in anti-tumor immunity of colorectal cancer
Tumor stroma-immune interactions shape the immunosuppressive microenvironment and predict response to neoadjuvant chemoradiotherapy plus immunotherapy in rectal cancer
Ascites reprograms innate lymphoid immune cells in ovarian cancer by promoting ILC2 enrichment and dysfunctional NK-cell states
Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-free adoptive TIL therapy
EUVIMED